Navigation Links
eResearchTechnology, Inc. and nSpire Health, Inc. Form Alliance to Deliver Integrated Cardiac Safety and Pulmonary Clinical Trial Services
Date:4/14/2008

PHILADELPHIA, April 14 /PRNewswire-FirstCall/ -- eResearchTechnology, Inc. (eRT), (Nasdaq: ERES), and nSpire Health, Inc. announced today their alliance to provide integrated Cardiac Safety and Pulmonary Core Lab Services to clinical researchers worldwide.

eResearchTechnology is a leading provider of centralized electrocardiographic (ECG), eClinical technology, ePRO, and other services to the pharmaceutical, biotechnology, medical device, and related industries. nSpire Health is a leading provider of respiratory clinical trials services, including Cardiopulmonary Exercise Testing, High Definition Pulmonary Diagnostics Systems, Spirometry, and Home Monitoring.

Under the agreement, eRT and nSpire will deliver a combined solution to meet the increased demand for cardio-pulmonary safety and efficacy services during clinical trials, in part caused by an increased interest in using inhaled therapeutics. The partnership will offer integrated services from project planning and set-up through study conduct, management, and data delivery for primary and secondary Cardiac and Respiratory clinical trial endpoints. nSpire Health will provide eSP(TM) Core Lab Data Management software, QA services, HDpft(TM), KoKo(R), PiKo(R), and PiKoLogic(TM) (electronic Diary) respiratory diagnostic measuring instruments. eRT will perform digital collection, measurement, interpretation, review, and distribution of cardiac safety data through its EXPeRT 2.0 workflow-enabled data management system.

"This alliance addresses a growing need in clinical research to offer comprehensive, best in class services in these two closely related areas of clinical study," said Michael McKelvey, President and CEO of eRT. "While many sponsors recognize and source each company for its respective area of expertise, customers increasingly seek consolidation and streamlining in all phases of a clinical trial. eRT and nSpire Health approach the market in the same way -- focusing on scientific excellence, providing a quality product, and client satisfaction. We are both metrics driven and process oriented to ensure on-time, on-budget, reliable data delivery on a global scale."

"Clinical trial sponsors have a strategic need to deliver accurate, cost- effective results in less time. They need therapeutic specialists that they can trust. This partnership leverages the world's most advanced Cardio- Respiratory specific technologies and data management services from each company into one unified source, reducing costs and accelerating time to market for emerging inhaled therapeutic trials," commented Michael S. Sims, President and CEO of nSpire Health, Inc.

About nSpire Health

nSpire Health develops and manufactures respiratory care products and provides related services in over 100 countries. The company is focused on cardiopulmonary diagnostics, respiratory core lab services, and disease management solutions designed to improve health care productivity while increasing the overall quality of patient care. nSpire Health is the exclusive provider of PiKo(R) home health monitors and HDpft(TM) systems, the most accurate and precise pulmonary function testing systems worldwide.

About eRT

Based in Philadelphia, Pa, eResearchTechnology, Inc. (http://www.eRT.com) is a provider of technology and services to the pharmaceutical, biotechnology and medical device industries on a global basis. The company is a market leader in providing centralized core-diagnostic electrocardiographic (ECG) technology and services to evaluate cardiac safety in clinical development. The company is also a leader in providing technology and services to streamline the clinical trials process by enabling its customers to automate the collection, analysis and distribution of clinical data in all phases of clinical development.

Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements, including, but not limited to, 2008 financial guidance, involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.


'/>"/>
SOURCE eResearchTechnology, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. eResearchTechnology, Inc. to Announce 2007 Fourth Quarter Results on February 26, 2008
2. Sticky mussels inspire biomedical engineer yet again
3. Good Neighbor Pharmacy(R) Ironman Competitor Inspires Individuals with Diabetes to Live Without Limits
4. MIT creates gecko-inspired bandage
5. Nanotechs health, environmental impacts worry scientists and the public
6. ETEX and LifeNet Health, Inc. Enter Agreement
7. IBF/LifeScience Alley MedTech Investing Conference Adds Ashley Boam, Acting Deputy Director for Science and Review Policy, Office of Device Evaluation, Center for Devices and Radiological Health, FDA
8. Heritage and Ipca Enter Into Strategic Alliance for Generic Pharmaceutical Products
9. Alliance for Medical Devices, Instrumentation and Diagnostics formed between Fraunhofer Center for Manufacturing Innovation and Boston University
10. Campbell Alliance to Moderate Senior-Level Panel Discussion at Windhover Pharmaceutical Strategic Alliances Conference
11. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016  Regular discussions on a range of subjects ... the two entities said Poloz. Speaking at a ... , he pointed to the country,s inflation target, which ... "In certain areas ... have common economic goals, why not sit down and address ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
(Date:6/23/2016)... Md. , June 23, 2016 A person ... from the crime scene to track the criminal down. ... the U.S. Food and Drug Administration (FDA) uses DNA evidence ... Sound far-fetched? It,s not. The FDA ... sequencing to support investigations of foodborne illnesses. Put as simply ...
(Date:6/23/2016)... NEW YORK , June, 23, 2016  The ... students to envision new ways to harness living systems ... of Modern Art (MoMA) in New York ... more than 130 participating students, showcased projects at MoMA,s ... included Paola Antonelli , MoMA,s senior curator of ...
Breaking Biology Technology:
(Date:5/24/2016)... facilitates superior patient care by providing unparalleled technology to leaders of the medical imaging ... product recently added to the range of products distributed by Ampronix. Photo ... ... ... News ...
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:4/28/2016)... , April 28, 2016 Infosys ... (NYSE: INFY ), and Samsung SDS, a global ... that will provide end customers with a more secure, fast ...      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) , ... but it also plays a fundamental part in enabling and ...
Breaking Biology News(10 mins):